Introduction:The pathological processes of pulmonary hypertension and COVID-19 disease are similar. Both are characterized by vascular damage, severe micro thrombosis, and microvascular obliterative disease due to extensive endothelial dysfunction.Objective:It was planned to present the clinical, radiological, and biochemical data of patients with pulmonary arterial hypertension(PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) diagnosed with COVID-19, who were followed up in our pulmonary arterial hypertension (PAH) center, as well as to assess the survival rates and to investigate the factors impacting survival.Methods: Patients who were diagnosed with COVID-19 between March 2020 and July 2021 and were followed up in the PAH center of our hospital, were included in the study. All information were obtained from the records in the hospital automation system. Results:It was found that 24(7.2%) of the 331 patients who had been followed in the PAH center were diagnosed with coronavirus. The mean age of the patients was determined to be 53.54. It was found that 62.5% of the patients were female,54.2% had the etiology of CTEPH and 41.7% of the patients were in functional class II(WHO-FC II) before being infected with COVID-19.The survival rate was 79.2%. It was found out that the risk of mortality decreased by 0.007 times as the cardiac index increased, and the risk of mortality increased 10,233 times as the functional class increased.Conclusion:Mortality rates due to COVID-19 infection were determined to be higher in PAH/CTEPH patients. The cardiac index values and current functional classes of the patients were associated with survival.